SG11202009179TA - Pyrazole compounds substituted with heteroaryl and pharmaceutical use thereof - Google Patents

Pyrazole compounds substituted with heteroaryl and pharmaceutical use thereof

Info

Publication number
SG11202009179TA
SG11202009179TA SG11202009179TA SG11202009179TA SG11202009179TA SG 11202009179T A SG11202009179T A SG 11202009179TA SG 11202009179T A SG11202009179T A SG 11202009179TA SG 11202009179T A SG11202009179T A SG 11202009179TA SG 11202009179T A SG11202009179T A SG 11202009179TA
Authority
SG
Singapore
Prior art keywords
heteroaryl
pharmaceutical use
compounds substituted
pyrazole compounds
pyrazole
Prior art date
Application number
SG11202009179TA
Other languages
English (en)
Inventor
Tomoya Miura
Shintaro Hirashima
Tomoyuki Manabe
Tetsuya Iida
Kentaro Sakurai
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of SG11202009179TA publication Critical patent/SG11202009179TA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11202009179TA 2018-04-04 2019-04-03 Pyrazole compounds substituted with heteroaryl and pharmaceutical use thereof SG11202009179TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018072557 2018-04-04
PCT/JP2019/014721 WO2019194207A1 (fr) 2018-04-04 2019-04-03 Composé de pyrazole substitué par hétéroaryle et son utilisation médicinale

Publications (1)

Publication Number Publication Date
SG11202009179TA true SG11202009179TA (en) 2020-10-29

Family

ID=68100257

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202009179TA SG11202009179TA (en) 2018-04-04 2019-04-03 Pyrazole compounds substituted with heteroaryl and pharmaceutical use thereof

Country Status (19)

Country Link
US (3) US10988462B2 (fr)
EP (1) EP3778593A4 (fr)
JP (3) JP7130588B2 (fr)
KR (1) KR20200139696A (fr)
CN (1) CN111902408B (fr)
AR (1) AR114465A1 (fr)
AU (1) AU2019249560B2 (fr)
BR (1) BR112020019939A2 (fr)
CA (1) CA3089092A1 (fr)
CL (1) CL2020002550A1 (fr)
CO (1) CO2020012353A2 (fr)
IL (1) IL277686A (fr)
MX (1) MX2020010433A (fr)
PE (1) PE20201068A1 (fr)
PH (1) PH12020551624A1 (fr)
SG (1) SG11202009179TA (fr)
TW (1) TWI805727B (fr)
WO (1) WO2019194207A1 (fr)
ZA (1) ZA202006053B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI805699B (zh) 2018-03-01 2023-06-21 日商日本煙草產業股份有限公司 甲基內醯胺環化合物及其用途
SG11202009179TA (en) * 2018-04-04 2020-10-29 Japan Tobacco Inc Pyrazole compounds substituted with heteroaryl and pharmaceutical use thereof
BR112022003323A2 (pt) * 2019-09-04 2022-05-24 Japan Tobacco Inc Método terapêutico ou profilático para diabetes usando medicina de combinação
US20230210831A1 (en) * 2019-09-04 2023-07-06 Japan Tobacco Inc. Chronic kidney disease treatment or prevention method
WO2021187548A1 (fr) 2020-03-19 2021-09-23 日本たばこ産業株式会社 Méthode de traitement ou de prévention des insuffisances cardiaques chroniques

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2665898B1 (fr) 1990-08-20 1994-03-11 Sanofi Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
JPH04247081A (ja) 1991-02-01 1992-09-03 Takeda Chem Ind Ltd 5員複素環酸アミド類
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
JPWO2004069824A1 (ja) 2003-02-07 2006-05-25 第一製薬株式会社 ピラゾール誘導体
AU2004200420A1 (en) 2003-03-11 2004-09-30 Astellas Pharma Inc. Inhibitor of cyclooxygenase
JP2006182648A (ja) 2003-04-08 2006-07-13 Dai Ichi Seiyaku Co Ltd 7員複素環誘導体
US20050075375A1 (en) 2003-05-14 2005-04-07 Anadys Pharmaceuticals, Inc. Heterocyclic compounds for treating hepatitis C virus
EP1637539B1 (fr) * 2003-06-20 2012-01-18 Kissei Pharmaceutical Co., Ltd. Derive de pyrazole, composition de medicaments contenant ledit derive et intermediaire de production associe
TW200526588A (en) 2003-11-17 2005-08-16 Smithkline Beecham Corp Chemical compounds
TW200526641A (en) 2003-12-26 2005-08-16 Daiichi Seiyaku Co Amidopyrazole derivatives
DE102004028241B4 (de) * 2004-06-11 2007-09-13 Sanofi-Aventis Deutschland Gmbh Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel
US7649009B2 (en) 2004-07-07 2010-01-19 Merck & Co., Inc. Pyrazole amide derivatives, compositions containing such compounds and methods of use
US9168278B2 (en) 2004-11-16 2015-10-27 Gw Pharma Limited Use for cannabinoid
KR20070084455A (ko) * 2004-11-23 2007-08-24 워너-램버트 캄파니 엘엘씨 지질혈증 치료용 hmg co-a 환원효소 억제제로서의7-(2h-피라졸-3-일)-3,5-디히드록시-헵탄산 유도체
JP2008007405A (ja) * 2004-12-07 2008-01-17 Takeda Chem Ind Ltd カルボキサミド誘導体
EP1889842A4 (fr) 2005-06-08 2009-07-29 Japan Tobacco Inc Composé hétérocyclique
JP4137956B2 (ja) 2005-06-08 2008-08-20 日本たばこ産業株式会社 複素環化合物
WO2007034279A2 (fr) 2005-09-19 2007-03-29 Pfizer Products Inc. Antagonistes de c3a et leurs compositions pharmaceutiques
TWI378922B (en) * 2005-10-21 2012-12-11 Mitsubishi Tanabe Pharma Corp A pyrazole compound
AU2007219509A1 (en) 2006-01-18 2007-09-07 Siena Biotech S.P.A Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof
US20080027014A1 (en) * 2006-07-28 2008-01-31 Tanabe Seiyaku Co., Ltd. Novel SGLT inhibitors
CA2675511A1 (fr) * 2006-10-10 2008-04-17 Amgen Inc. Composes de n-arylpyrazole a utiliser contre le diabete
WO2008061796A2 (fr) 2006-11-24 2008-05-29 Ac Immune Sa Nouveaux composés destinés au traitement de maladies associés à des protéines amyloïdes ou de type amyloïde
CA2670418A1 (fr) 2006-11-24 2008-05-29 Ac Immune Sa Nouveaux composes destines au traitement de maladies associes a des proteines amyloides ou de type amyloide
CL2008000119A1 (es) 2007-01-16 2008-05-16 Wyeth Corp Compuestos derivados de pirazol, antagonistas del receptor nicotinico de acetilcolina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como demencia senil, alzheimer y esquizofrenia.
JP4994295B2 (ja) * 2007-04-20 2012-08-08 田辺三菱製薬株式会社 医薬組成物
US20090181952A1 (en) 2008-01-14 2009-07-16 Wyeth Compounds useful as alpha7 nicotinic acetylcholine receptor agonists
EA201100189A1 (ru) 2008-07-15 2011-08-30 Новартис Аг Гетероарильные производные в качестве ингибиторов dgat1
NZ718622A (en) 2010-03-30 2018-03-23 Verseon Corp Multisubstituted aromatic compounds as inhibitors of thrombin
WO2011161615A1 (fr) * 2010-06-24 2011-12-29 Ranbaxy Laboratories Limited Inhibiteurs de la 5-lipoxygénase
AR087701A1 (es) 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1
UA113086C2 (xx) * 2012-05-10 2016-12-12 Піразольні сполуки як інгібітори sglt1
CN111303159A (zh) * 2014-10-02 2020-06-19 豪夫迈·罗氏有限公司 用于治疗由布鲁顿酪氨酸激酶(btk)介导的疾病的吡唑甲酰胺化合物
TWI805699B (zh) 2018-03-01 2023-06-21 日商日本煙草產業股份有限公司 甲基內醯胺環化合物及其用途
SG11202009179TA (en) * 2018-04-04 2020-10-29 Japan Tobacco Inc Pyrazole compounds substituted with heteroaryl and pharmaceutical use thereof

Also Published As

Publication number Publication date
AU2019249560A1 (en) 2020-07-23
JP2022166280A (ja) 2022-11-01
CO2020012353A2 (es) 2021-01-18
JP2019182852A (ja) 2019-10-24
RU2020132318A3 (fr) 2022-04-29
WO2019194207A1 (fr) 2019-10-10
CN111902408A (zh) 2020-11-06
EP3778593A1 (fr) 2021-02-17
RU2020132318A (ru) 2022-04-29
PH12020551624A1 (en) 2021-07-12
US20220048896A1 (en) 2022-02-17
AU2019249560B2 (en) 2023-10-05
BR112020019939A2 (pt) 2021-01-05
CL2020002550A1 (es) 2021-01-15
KR20200139696A (ko) 2020-12-14
MX2020010433A (es) 2020-10-28
TWI805727B (zh) 2023-06-21
EP3778593A4 (fr) 2021-12-22
PE20201068A1 (es) 2020-10-19
CA3089092A1 (fr) 2019-10-10
JP2024050645A (ja) 2024-04-10
US20190330193A1 (en) 2019-10-31
CN111902408B (zh) 2023-11-14
US10988462B2 (en) 2021-04-27
US20240166632A1 (en) 2024-05-23
AR114465A1 (es) 2020-09-09
JP7130588B2 (ja) 2022-09-05
TW201942114A (zh) 2019-11-01
IL277686A (en) 2020-11-30
ZA202006053B (en) 2022-03-30

Similar Documents

Publication Publication Date Title
ZA202001340B (en) Heterocyclic compound and use thereof
EP3594203A4 (fr) Composé de pyrrolidine substituée et son utilisation
EP3594202A4 (fr) Composé de pyrrolidine substituée et son utilisation
IL277686A (en) Heteroaryl-substituted pyrazole compounds and their pharmaceutical use
IL290745A (en) A pyrimidine compound and its pharmaceutical use
ZA202007547B (en) Heteroaryl compounds and uses thereof
IL273339A (en) Griseofulbin compound and its medical use
EP3344613A4 (fr) Composés hétéroaryle et leur utilisation comme médicaments thérapeutiques
IL273573A (en) Nitrogen-containing heteroaryl compound and medicinal use thereof
IL267626A (en) Teraaryl compounds and their uses
IL276290A (en) Heteroaryl compounds, their pharmaceutical preparations and their medical use
IL276323A (en) 4-Methyldihydropyrimidinone compounds and their pharmaceutical use
EP3681877A4 (fr) Composé dérivé de pyrazole et son utilisation
IL276912A (en) Heterocyclic compound and its use
SG11202007119UA (en) Saturated-ring-fused dihydropyrimidinone or dihydrotriazinone compounds and pharmaceutical use thereof
EP3851108C0 (fr) Médicament à base de borate et utilisation associée
EP3696178A4 (fr) Composé hétérocyclique et son application en médecine
EP3568137A4 (fr) Composés hétérocycliques et utilisation de ces composés
IL276410A (en) Pyrazole compounds and their preparation
ZA202000959B (en) Adamantylmethylamine derivative and use thereof as pharmaceutical
EP3845528A4 (fr) Composés de pyrazole, compositions pharmaceutiques correspondantes et utilisation associées
EP3718543A4 (fr) Composition pharmaceutique et son utilisation
IL283315A (en) Heterocyclic compounds and medical use thereof